Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heart Failure | 395 | 2025 | 11860 | 13.280 |
Why?
|
Stroke Volume | 296 | 2025 | 5620 | 9.990 |
Why?
|
Angiotensin Receptor Antagonists | 101 | 2024 | 1066 | 6.880 |
Why?
|
Tetrazoles | 89 | 2024 | 923 | 6.560 |
Why?
|
Biphenyl Compounds | 102 | 2024 | 1026 | 5.750 |
Why?
|
Ventricular Function, Left | 134 | 2025 | 3942 | 4.750 |
Why?
|
Spironolactone | 41 | 2024 | 412 | 3.920 |
Why?
|
Drug Combinations | 90 | 2024 | 2078 | 3.760 |
Why?
|
Ventricular Dysfunction, Left | 45 | 2024 | 2144 | 3.490 |
Why?
|
Naphthyridines | 15 | 2025 | 181 | 3.090 |
Why?
|
Glucosides | 27 | 2024 | 533 | 3.070 |
Why?
|
Influenza Vaccines | 24 | 2025 | 780 | 2.990 |
Why?
|
Natriuretic Peptide, Brain | 56 | 2024 | 1751 | 2.950 |
Why?
|
Benzhydryl Compounds | 35 | 2024 | 940 | 2.920 |
Why?
|
Enalapril | 28 | 2024 | 316 | 2.860 |
Why?
|
Neprilysin | 33 | 2024 | 487 | 2.610 |
Why?
|
Influenza, Human | 27 | 2025 | 1539 | 2.580 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 44 | 2024 | 1517 | 2.230 |
Why?
|
Hospitalization | 81 | 2024 | 10844 | 1.810 |
Why?
|
Peptide Fragments | 48 | 2024 | 5151 | 1.790 |
Why?
|
Glomerular Filtration Rate | 27 | 2025 | 2226 | 1.520 |
Why?
|
Myocardial Infarction | 36 | 2025 | 11515 | 1.470 |
Why?
|
Aged | 317 | 2025 | 171544 | 1.450 |
Why?
|
Diabetes Mellitus, Type 2 | 45 | 2024 | 12239 | 1.340 |
Why?
|
Echocardiography | 44 | 2024 | 5044 | 1.330 |
Why?
|
Double-Blind Method | 79 | 2025 | 12457 | 1.300 |
Why?
|
Cardiovascular Diseases | 58 | 2024 | 15652 | 1.280 |
Why?
|
Renal Insufficiency, Chronic | 24 | 2024 | 2295 | 1.270 |
Why?
|
Randomized Controlled Trials as Topic | 38 | 2025 | 10377 | 1.260 |
Why?
|
Atherosclerosis | 26 | 2024 | 3431 | 1.250 |
Why?
|
Humans | 568 | 2025 | 768298 | 1.230 |
Why?
|
Cardiomyopathy, Hypertrophic | 10 | 2024 | 1335 | 1.200 |
Why?
|
Blood Pressure | 30 | 2024 | 8541 | 1.140 |
Why?
|
Male | 365 | 2025 | 364870 | 1.120 |
Why?
|
Middle Aged | 274 | 2025 | 223463 | 1.100 |
Why?
|
Pulmonary Edema | 7 | 2024 | 409 | 1.080 |
Why?
|
Female | 365 | 2025 | 397050 | 1.060 |
Why?
|
Treatment Outcome | 131 | 2025 | 65365 | 1.050 |
Why?
|
Data Interpretation, Statistical | 9 | 2021 | 2708 | 1.050 |
Why?
|
Troponin T | 11 | 2024 | 787 | 1.020 |
Why?
|
Urea | 9 | 2024 | 446 | 1.010 |
Why?
|
Atrial Fibrillation | 22 | 2024 | 5168 | 1.010 |
Why?
|
Diabetes Mellitus | 21 | 2024 | 5890 | 0.980 |
Why?
|
Prognosis | 99 | 2024 | 30020 | 0.980 |
Why?
|
Ramipril | 10 | 2024 | 102 | 0.950 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 15 | 2024 | 429 | 0.930 |
Why?
|
Vaccination | 22 | 2025 | 3431 | 0.880 |
Why?
|
Heart Ventricles | 17 | 2024 | 3838 | 0.850 |
Why?
|
Heart Failure, Diastolic | 5 | 2024 | 77 | 0.840 |
Why?
|
Endpoint Determination | 6 | 2019 | 594 | 0.820 |
Why?
|
Hypertension | 23 | 2023 | 8615 | 0.790 |
Why?
|
Aged, 80 and over | 101 | 2024 | 59683 | 0.780 |
Why?
|
Hypotension | 8 | 2024 | 889 | 0.760 |
Why?
|
Atrial Function, Left | 7 | 2021 | 188 | 0.730 |
Why?
|
Troponin I | 6 | 2024 | 662 | 0.730 |
Why?
|
Heart Atria | 13 | 2022 | 1360 | 0.710 |
Why?
|
Prospective Studies | 95 | 2024 | 54921 | 0.710 |
Why?
|
Risk Factors | 107 | 2024 | 74954 | 0.700 |
Why?
|
Cause of Death | 25 | 2024 | 3728 | 0.670 |
Why?
|
Hematinics | 7 | 2023 | 282 | 0.660 |
Why?
|
Antihypertensive Agents | 13 | 2023 | 2027 | 0.650 |
Why?
|
Acute Coronary Syndrome | 10 | 2023 | 2192 | 0.640 |
Why?
|
Hyperkalemia | 8 | 2023 | 233 | 0.640 |
Why?
|
Prealbumin | 7 | 2024 | 259 | 0.620 |
Why?
|
Risk Assessment | 44 | 2024 | 24316 | 0.620 |
Why?
|
Ventricular Remodeling | 14 | 2024 | 1281 | 0.610 |
Why?
|
Heart Failure, Systolic | 4 | 2023 | 135 | 0.600 |
Why?
|
Benzimidazoles | 6 | 2020 | 864 | 0.600 |
Why?
|
Hypertrophy, Left Ventricular | 9 | 2022 | 856 | 0.590 |
Why?
|
Cardiomyopathies | 9 | 2024 | 2056 | 0.580 |
Why?
|
Proportional Hazards Models | 29 | 2024 | 12557 | 0.580 |
Why?
|
Hypoglycemic Agents | 13 | 2024 | 3108 | 0.570 |
Why?
|
Ventricular Dysfunction, Right | 5 | 2024 | 644 | 0.570 |
Why?
|
Death, Sudden, Cardiac | 7 | 2024 | 1568 | 0.560 |
Why?
|
Stroke | 19 | 2023 | 9742 | 0.560 |
Why?
|
Kidney | 19 | 2024 | 7063 | 0.550 |
Why?
|
Natriuretic Peptides | 8 | 2023 | 156 | 0.550 |
Why?
|
Life Expectancy | 3 | 2018 | 1249 | 0.530 |
Why?
|
Exercise Test | 6 | 2024 | 2186 | 0.530 |
Why?
|
Exercise Tolerance | 6 | 2024 | 848 | 0.530 |
Why?
|
Anemia | 7 | 2024 | 1520 | 0.520 |
Why?
|
Echocardiography, Doppler | 11 | 2020 | 899 | 0.500 |
Why?
|
Kidney Failure, Chronic | 9 | 2024 | 2491 | 0.490 |
Why?
|
Time Factors | 46 | 2024 | 40267 | 0.490 |
Why?
|
Quality of Life | 24 | 2024 | 13499 | 0.490 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2018 | 876 | 0.480 |
Why?
|
Amyloid Neuropathies, Familial | 3 | 2023 | 180 | 0.480 |
Why?
|
Denmark | 10 | 2025 | 779 | 0.440 |
Why?
|
Research Design | 9 | 2023 | 6209 | 0.440 |
Why?
|
Angiotensins | 7 | 2024 | 141 | 0.440 |
Why?
|
Follow-Up Studies | 51 | 2024 | 39405 | 0.440 |
Why?
|
Hypokalemia | 5 | 2019 | 153 | 0.430 |
Why?
|
Prediabetic State | 4 | 2022 | 548 | 0.430 |
Why?
|
Sex Factors | 23 | 2025 | 10656 | 0.420 |
Why?
|
Diastole | 11 | 2023 | 784 | 0.410 |
Why?
|
Survival Rate | 27 | 2022 | 12870 | 0.410 |
Why?
|
Incidence | 36 | 2024 | 21544 | 0.410 |
Why?
|
Diabetic Angiopathies | 4 | 2020 | 806 | 0.400 |
Why?
|
Diuretics | 7 | 2023 | 612 | 0.400 |
Why?
|
Polypharmacy | 3 | 2024 | 307 | 0.390 |
Why?
|
Proteomics | 6 | 2024 | 3906 | 0.390 |
Why?
|
Coronary Disease | 7 | 2023 | 5926 | 0.370 |
Why?
|
Defibrillators, Implantable | 5 | 2021 | 1498 | 0.360 |
Why?
|
Potassium | 5 | 2025 | 1319 | 0.360 |
Why?
|
Kaplan-Meier Estimate | 14 | 2024 | 6541 | 0.360 |
Why?
|
Adrenergic beta-Antagonists | 6 | 2023 | 1244 | 0.360 |
Why?
|
Longitudinal Studies | 13 | 2023 | 14783 | 0.350 |
Why?
|
Rectal Neoplasms | 1 | 2019 | 1185 | 0.340 |
Why?
|
Health Status | 9 | 2024 | 4094 | 0.340 |
Why?
|
Erythropoietin | 3 | 2023 | 719 | 0.340 |
Why?
|
Mortality | 9 | 2024 | 2917 | 0.330 |
Why?
|
Systole | 10 | 2023 | 937 | 0.330 |
Why?
|
Coronary Artery Disease | 9 | 2023 | 6566 | 0.330 |
Why?
|
Diabetic Nephropathies | 5 | 2023 | 975 | 0.330 |
Why?
|
Benzylamines | 6 | 2024 | 251 | 0.320 |
Why?
|
United States | 59 | 2024 | 73144 | 0.320 |
Why?
|
Survival Analysis | 12 | 2022 | 10117 | 0.320 |
Why?
|
Heart-Assist Devices | 5 | 2022 | 1292 | 0.320 |
Why?
|
Blood Glucose | 11 | 2024 | 6430 | 0.320 |
Why?
|
Uracil | 6 | 2024 | 210 | 0.320 |
Why?
|
Predictive Value of Tests | 22 | 2024 | 15455 | 0.300 |
Why?
|
Obesity | 14 | 2024 | 13082 | 0.300 |
Why?
|
Death, Sudden | 3 | 2022 | 301 | 0.300 |
Why?
|
Biometry | 1 | 2011 | 565 | 0.300 |
Why?
|
Peptides | 7 | 2023 | 4352 | 0.290 |
Why?
|
Thiazolidinediones | 1 | 2011 | 461 | 0.290 |
Why?
|
Amyloidosis | 3 | 2024 | 879 | 0.290 |
Why?
|
Renal Dialysis | 5 | 2023 | 1802 | 0.280 |
Why?
|
Atrial Function, Right | 2 | 2018 | 32 | 0.280 |
Why?
|
Propanolamines | 2 | 2018 | 164 | 0.280 |
Why?
|
Laparoscopy | 1 | 2019 | 2034 | 0.280 |
Why?
|
Clinical Trials as Topic | 11 | 2024 | 8051 | 0.280 |
Why?
|
Neoplasms | 10 | 2023 | 22389 | 0.280 |
Why?
|
Heart | 6 | 2023 | 4449 | 0.280 |
Why?
|
Heart Rate | 8 | 2023 | 4218 | 0.270 |
Why?
|
Cohort Studies | 31 | 2024 | 41791 | 0.270 |
Why?
|
Kidney Diseases | 4 | 2023 | 2103 | 0.270 |
Why?
|
Europe | 11 | 2023 | 3439 | 0.270 |
Why?
|
Gastrointestinal Agents | 2 | 2021 | 510 | 0.260 |
Why?
|
Thrombolytic Therapy | 2 | 2023 | 2050 | 0.250 |
Why?
|
Furosemide | 3 | 2023 | 171 | 0.250 |
Why?
|
Smoking | 8 | 2021 | 9109 | 0.250 |
Why?
|
Sex Characteristics | 5 | 2023 | 2661 | 0.250 |
Why?
|
Immunotherapy | 2 | 2018 | 4740 | 0.250 |
Why?
|
Sample Size | 5 | 2017 | 848 | 0.250 |
Why?
|
Intestinal Mucosa | 5 | 2020 | 3048 | 0.250 |
Why?
|
Crohn Disease | 4 | 2021 | 2293 | 0.250 |
Why?
|
Cardiovascular Agents | 2 | 2024 | 849 | 0.240 |
Why?
|
Ventricular Function, Right | 3 | 2024 | 628 | 0.240 |
Why?
|
Correspondence as Topic | 1 | 2024 | 34 | 0.240 |
Why?
|
Albuminuria | 5 | 2023 | 658 | 0.230 |
Why?
|
Recurrence | 7 | 2024 | 8501 | 0.230 |
Why?
|
Adult | 58 | 2024 | 223622 | 0.230 |
Why?
|
Comorbidity | 17 | 2021 | 10588 | 0.230 |
Why?
|
Clinical Trials Data Monitoring Committees | 1 | 2024 | 25 | 0.230 |
Why?
|
Coronary Stenosis | 2 | 2020 | 802 | 0.230 |
Why?
|
Gastrointestinal Hemorrhage | 3 | 2017 | 1126 | 0.230 |
Why?
|
Heart Arrest | 6 | 2019 | 1516 | 0.220 |
Why?
|
Disease Progression | 17 | 2024 | 13646 | 0.220 |
Why?
|
Extracellular Matrix | 3 | 2020 | 1739 | 0.220 |
Why?
|
Dyspnea | 5 | 2023 | 1351 | 0.220 |
Why?
|
Matrix Metalloproteinase 2 | 2 | 2023 | 462 | 0.220 |
Why?
|
Registries | 10 | 2024 | 8378 | 0.210 |
Why?
|
Multiple Sclerosis | 1 | 2018 | 3247 | 0.210 |
Why?
|
Receptors, Angiotensin | 4 | 2024 | 141 | 0.210 |
Why?
|
Echocardiography, Doppler, Color | 2 | 2014 | 353 | 0.210 |
Why?
|
Outpatients | 5 | 2024 | 1603 | 0.210 |
Why?
|
Protease Inhibitors | 2 | 2016 | 752 | 0.210 |
Why?
|
Electrocardiography | 6 | 2024 | 6409 | 0.200 |
Why?
|
Fumarates | 2 | 2020 | 132 | 0.200 |
Why?
|
Age Factors | 15 | 2024 | 18472 | 0.200 |
Why?
|
Brain Ischemia | 3 | 2023 | 3008 | 0.200 |
Why?
|
Immunization Schedule | 2 | 2024 | 228 | 0.200 |
Why?
|
Dose-Response Relationship, Drug | 12 | 2024 | 10776 | 0.200 |
Why?
|
Hospital Mortality | 10 | 2024 | 5367 | 0.200 |
Why?
|
Myocardium | 5 | 2024 | 4788 | 0.190 |
Why?
|
Cardiac Resynchronization Therapy | 2 | 2018 | 559 | 0.190 |
Why?
|
Microscopy, Confocal | 4 | 2016 | 1972 | 0.190 |
Why?
|
Growth Differentiation Factor 15 | 2 | 2024 | 199 | 0.190 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 4 | 2021 | 3242 | 0.190 |
Why?
|
Amyloidosis, Familial | 1 | 2021 | 16 | 0.190 |
Why?
|
Ferritins | 3 | 2024 | 601 | 0.190 |
Why?
|
Antibody Formation | 2 | 2023 | 1393 | 0.190 |
Why?
|
Models, Statistical | 5 | 2020 | 5099 | 0.180 |
Why?
|
Seasons | 2 | 2024 | 1526 | 0.180 |
Why?
|
Creatinine | 7 | 2024 | 1915 | 0.180 |
Why?
|
Macula Lutea | 1 | 2022 | 180 | 0.180 |
Why?
|
Diabetes Complications | 3 | 2020 | 1322 | 0.180 |
Why?
|
Multiple Myeloma | 1 | 2018 | 5192 | 0.180 |
Why?
|
Amides | 2 | 2020 | 452 | 0.180 |
Why?
|
Ventricular Pressure | 1 | 2021 | 210 | 0.180 |
Why?
|
Placebos | 3 | 2020 | 1668 | 0.180 |
Why?
|
Internationality | 5 | 2019 | 1008 | 0.170 |
Why?
|
North America | 6 | 2020 | 1290 | 0.170 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2018 | 5711 | 0.170 |
Why?
|
Placebo Effect | 2 | 2015 | 518 | 0.170 |
Why?
|
Biological Factors | 1 | 2021 | 158 | 0.170 |
Why?
|
Edema, Cardiac | 1 | 2019 | 19 | 0.170 |
Why?
|
Body Mass Index | 9 | 2024 | 13050 | 0.170 |
Why?
|
Echocardiography, Doppler, Pulsed | 1 | 2019 | 69 | 0.170 |
Why?
|
Multicenter Studies as Topic | 3 | 2021 | 1727 | 0.170 |
Why?
|
Ultrasonography | 8 | 2021 | 6001 | 0.170 |
Why?
|
Vital Capacity | 2 | 2022 | 984 | 0.170 |
Why?
|
Hemostasis, Endoscopic | 2 | 2017 | 42 | 0.170 |
Why?
|
Tricuspid Valve Insufficiency | 1 | 2024 | 362 | 0.170 |
Why?
|
Metformin | 2 | 2019 | 911 | 0.170 |
Why?
|
Diuretics, Osmotic | 1 | 2019 | 33 | 0.160 |
Why?
|
Hypercholesterolemia | 2 | 2018 | 1142 | 0.160 |
Why?
|
Drug Labeling | 1 | 2021 | 250 | 0.160 |
Why?
|
Severity of Illness Index | 16 | 2021 | 15939 | 0.160 |
Why?
|
Adrenergic beta-2 Receptor Agonists | 1 | 2019 | 110 | 0.160 |
Why?
|
Hyperaldosteronism | 1 | 2022 | 250 | 0.160 |
Why?
|
Cardiac Myosins | 3 | 2024 | 128 | 0.160 |
Why?
|
Mannitol | 1 | 2019 | 177 | 0.160 |
Why?
|
International Classification of Diseases | 2 | 2021 | 924 | 0.150 |
Why?
|
Sodium-Glucose Transporter 1 | 1 | 2018 | 108 | 0.150 |
Why?
|
Heart Diseases | 2 | 2022 | 2819 | 0.150 |
Why?
|
Models, Cardiovascular | 1 | 2024 | 984 | 0.150 |
Why?
|
Cardiac Resynchronization Therapy Devices | 1 | 2019 | 122 | 0.150 |
Why?
|
C-Reactive Protein | 6 | 2024 | 3859 | 0.150 |
Why?
|
Atrial Appendage | 1 | 2022 | 285 | 0.150 |
Why?
|
HIV Infections | 4 | 2024 | 17575 | 0.150 |
Why?
|
Hyperemia | 1 | 2019 | 224 | 0.150 |
Why?
|
Valine | 3 | 2014 | 410 | 0.150 |
Why?
|
Pneumonia | 3 | 2024 | 2162 | 0.150 |
Why?
|
Uric Acid | 2 | 2023 | 806 | 0.150 |
Why?
|
Acute Disease | 7 | 2024 | 7242 | 0.150 |
Why?
|
Kidney Transplantation | 3 | 2018 | 4300 | 0.150 |
Why?
|
Critical Care | 2 | 2021 | 2716 | 0.150 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2023 | 523 | 0.150 |
Why?
|
Vasodilator Agents | 4 | 2023 | 990 | 0.150 |
Why?
|
Patient Readmission | 3 | 2024 | 3312 | 0.150 |
Why?
|
Canrenone | 1 | 2017 | 5 | 0.150 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2018 | 208 | 0.140 |
Why?
|
Intestinal Absorption | 1 | 2018 | 400 | 0.140 |
Why?
|
Cardiac Volume | 1 | 2018 | 197 | 0.140 |
Why?
|
Ileum | 3 | 2020 | 558 | 0.140 |
Why?
|
Virus Diseases | 1 | 2023 | 723 | 0.140 |
Why?
|
Apolipoprotein E4 | 1 | 2021 | 711 | 0.140 |
Why?
|
Adiposity | 2 | 2018 | 1895 | 0.140 |
Why?
|
Magnetic Resonance Imaging, Cine | 1 | 2024 | 1092 | 0.140 |
Why?
|
Retinal Vessels | 2 | 2022 | 864 | 0.140 |
Why?
|
Myocardial Contraction | 3 | 2024 | 1527 | 0.140 |
Why?
|
Area Under Curve | 2 | 2018 | 1642 | 0.140 |
Why?
|
Blood Urea Nitrogen | 1 | 2017 | 187 | 0.140 |
Why?
|
Sleep Apnea, Obstructive | 3 | 2015 | 1891 | 0.140 |
Why?
|
Estradiol | 1 | 2024 | 1952 | 0.140 |
Why?
|
Hypoglycemia | 2 | 2022 | 894 | 0.140 |
Why?
|
Cross-Sectional Studies | 14 | 2024 | 26373 | 0.140 |
Why?
|
Drug Therapy, Combination | 7 | 2024 | 6319 | 0.140 |
Why?
|
Digoxin | 2 | 2022 | 246 | 0.140 |
Why?
|
Duodenal Diseases | 1 | 2017 | 101 | 0.140 |
Why?
|
Pleural Effusion | 1 | 2020 | 344 | 0.130 |
Why?
|
beta Carotene | 1 | 2018 | 523 | 0.130 |
Why?
|
Retrospective Studies | 26 | 2023 | 81768 | 0.130 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 3 | 2023 | 152 | 0.130 |
Why?
|
Multivariate Analysis | 10 | 2020 | 12092 | 0.130 |
Why?
|
Blood Pressure Determination | 1 | 2020 | 646 | 0.130 |
Why?
|
Hyperglycemia | 3 | 2020 | 1389 | 0.130 |
Why?
|
Esophageal Diseases | 1 | 2017 | 168 | 0.130 |
Why?
|
Hemoglobins | 2 | 2023 | 1532 | 0.130 |
Why?
|
Proton Pump Inhibitors | 1 | 2021 | 553 | 0.130 |
Why?
|
Russia | 4 | 2018 | 386 | 0.130 |
Why?
|
Retinal Artery | 1 | 2016 | 109 | 0.130 |
Why?
|
Troponin | 1 | 2019 | 534 | 0.130 |
Why?
|
Gout | 1 | 2023 | 621 | 0.130 |
Why?
|
Stomach Diseases | 1 | 2017 | 134 | 0.130 |
Why?
|
Health Status Disparities | 2 | 2018 | 1882 | 0.130 |
Why?
|
Chronic Disease | 8 | 2024 | 9380 | 0.130 |
Why?
|
Young Adult | 18 | 2024 | 60048 | 0.130 |
Why?
|
Natural Language Processing | 1 | 2024 | 1202 | 0.130 |
Why?
|
Vascular Resistance | 2 | 2015 | 940 | 0.130 |
Why?
|
Pandemics | 5 | 2023 | 8750 | 0.120 |
Why?
|
Chi-Square Distribution | 6 | 2017 | 3438 | 0.120 |
Why?
|
Therapeutics | 1 | 2015 | 113 | 0.120 |
Why?
|
Glucose Tolerance Test | 1 | 2018 | 1183 | 0.120 |
Why?
|
Myocardial Ischemia | 2 | 2023 | 2139 | 0.120 |
Why?
|
Hypertrophy, Right Ventricular | 1 | 2015 | 109 | 0.120 |
Why?
|
Prehypertension | 1 | 2015 | 63 | 0.120 |
Why?
|
Calcinosis | 1 | 2024 | 1482 | 0.120 |
Why?
|
Heart Valve Diseases | 1 | 2022 | 1031 | 0.120 |
Why?
|
Longevity | 2 | 2020 | 1077 | 0.120 |
Why?
|
Diabetic Neuropathies | 1 | 2018 | 411 | 0.120 |
Why?
|
Pulmonary Artery | 1 | 2023 | 1945 | 0.120 |
Why?
|
Cardiomyopathy, Restrictive | 1 | 2015 | 61 | 0.120 |
Why?
|
Prevalence | 11 | 2020 | 15868 | 0.120 |
Why?
|
Guidelines as Topic | 1 | 2021 | 1397 | 0.120 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2020 | 672 | 0.120 |
Why?
|
Insulin | 3 | 2018 | 6608 | 0.120 |
Why?
|
Captopril | 1 | 2015 | 262 | 0.120 |
Why?
|
Alcohol Drinking | 3 | 2019 | 4049 | 0.120 |
Why?
|
Lung | 7 | 2023 | 10087 | 0.110 |
Why?
|
Aging | 3 | 2020 | 8764 | 0.110 |
Why?
|
Exercise | 4 | 2019 | 5947 | 0.110 |
Why?
|
Hypertension, Pulmonary | 2 | 2015 | 1597 | 0.110 |
Why?
|
Ventricular Fibrillation | 1 | 2017 | 537 | 0.110 |
Why?
|
Pre-Eclampsia | 1 | 2023 | 1255 | 0.110 |
Why?
|
Echocardiography, Three-Dimensional | 2 | 2018 | 614 | 0.110 |
Why?
|
Insulin Resistance | 2 | 2021 | 3981 | 0.110 |
Why?
|
Hemagglutination Inhibition Tests | 2 | 2024 | 87 | 0.110 |
Why?
|
Patient Dropouts | 1 | 2016 | 411 | 0.110 |
Why?
|
Endoscopy, Digestive System | 1 | 2016 | 357 | 0.110 |
Why?
|
Tissue Survival | 1 | 2014 | 120 | 0.110 |
Why?
|
Delivery, Obstetric | 1 | 2021 | 952 | 0.110 |
Why?
|
Aortic Valve | 1 | 2024 | 1970 | 0.110 |
Why?
|
Ankle Brachial Index | 1 | 2014 | 163 | 0.110 |
Why?
|
Geriatric Assessment | 2 | 2019 | 1422 | 0.110 |
Why?
|
Hemodynamics | 4 | 2021 | 4199 | 0.110 |
Why?
|
Electric Countershock | 1 | 2017 | 534 | 0.110 |
Why?
|
Vascular Diseases | 1 | 2022 | 1161 | 0.110 |
Why?
|
Transplantation, Autologous | 1 | 2018 | 2127 | 0.110 |
Why?
|
Dietary Carbohydrates | 1 | 2018 | 897 | 0.110 |
Why?
|
Forced Expiratory Volume | 1 | 2018 | 1820 | 0.110 |
Why?
|
United States Food and Drug Administration | 1 | 2021 | 1672 | 0.110 |
Why?
|
Coronary Artery Bypass | 1 | 2022 | 2194 | 0.110 |
Why?
|
Gastric Mucosa | 1 | 2016 | 602 | 0.110 |
Why?
|
Frail Elderly | 1 | 2018 | 775 | 0.100 |
Why?
|
Cost of Illness | 2 | 2024 | 1959 | 0.100 |
Why?
|
Algorithms | 4 | 2024 | 14154 | 0.100 |
Why?
|
Patients | 2 | 2021 | 909 | 0.100 |
Why?
|
Georgia (Republic) | 3 | 2018 | 39 | 0.100 |
Why?
|
Malnutrition | 1 | 2019 | 631 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3118 | 0.100 |
Why?
|
Government | 2 | 2023 | 161 | 0.100 |
Why?
|
Colitis, Ulcerative | 2 | 2017 | 1929 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3241 | 0.100 |
Why?
|
Argentina | 3 | 2018 | 249 | 0.100 |
Why?
|
Aftercare | 3 | 2023 | 920 | 0.100 |
Why?
|
Drug Therapy | 1 | 2015 | 504 | 0.100 |
Why?
|
Colonoscopy | 2 | 2020 | 1412 | 0.100 |
Why?
|
Influenza A virus | 1 | 2015 | 460 | 0.100 |
Why?
|
Case-Control Studies | 9 | 2024 | 22292 | 0.100 |
Why?
|
Colchicine | 2 | 2023 | 257 | 0.100 |
Why?
|
Oxygen Consumption | 3 | 2024 | 1882 | 0.100 |
Why?
|
Meta-Analysis as Topic | 2 | 2021 | 1364 | 0.100 |
Why?
|
Peripheral Arterial Disease | 1 | 2023 | 1303 | 0.100 |
Why?
|
Nervous System | 1 | 2015 | 547 | 0.100 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 691 | 0.100 |
Why?
|
Computer Simulation | 4 | 2018 | 6277 | 0.100 |
Why?
|
Sweden | 3 | 2020 | 1383 | 0.100 |
Why?
|
Social Behavior | 1 | 2018 | 1146 | 0.090 |
Why?
|
Canada | 4 | 2018 | 2139 | 0.090 |
Why?
|
Malaria | 1 | 2021 | 1241 | 0.090 |
Why?
|
Adolescent | 14 | 2024 | 89182 | 0.090 |
Why?
|
Antibodies, Viral | 4 | 2024 | 3211 | 0.090 |
Why?
|
Aortic Valve Stenosis | 1 | 2024 | 2034 | 0.090 |
Why?
|
Vaccines, Inactivated | 2 | 2023 | 185 | 0.090 |
Why?
|
Organ Transplantation | 1 | 2021 | 1177 | 0.090 |
Why?
|
Radiotherapy | 1 | 2018 | 1509 | 0.090 |
Why?
|
Coronary Angiography | 2 | 2020 | 4537 | 0.090 |
Why?
|
Venous Thromboembolism | 1 | 2024 | 1881 | 0.090 |
Why?
|
Los Angeles | 2 | 2022 | 245 | 0.090 |
Why?
|
Income | 1 | 2019 | 1877 | 0.090 |
Why?
|
Heart Transplantation | 2 | 2022 | 3300 | 0.090 |
Why?
|
Patient Acceptance of Health Care | 1 | 2024 | 3230 | 0.090 |
Why?
|
Adrenal Cortex Hormones | 1 | 2019 | 1890 | 0.090 |
Why?
|
Endoscopy, Gastrointestinal | 2 | 2017 | 887 | 0.090 |
Why?
|
Pulmonary Circulation | 2 | 2024 | 744 | 0.090 |
Why?
|
New York | 2 | 2023 | 884 | 0.090 |
Why?
|
Health Status Indicators | 1 | 2015 | 971 | 0.090 |
Why?
|
Protein Kinase Inhibitors | 3 | 2015 | 5707 | 0.090 |
Why?
|
Stem Cell Transplantation | 1 | 2018 | 1601 | 0.090 |
Why?
|
Renal Insufficiency | 1 | 2016 | 809 | 0.090 |
Why?
|
Cardiology | 1 | 2021 | 1701 | 0.080 |
Why?
|
RNA, Small Interfering | 1 | 2019 | 3436 | 0.080 |
Why?
|
Cognition | 2 | 2024 | 7074 | 0.080 |
Why?
|
Single-Blind Method | 3 | 2019 | 1585 | 0.080 |
Why?
|
Thromboembolism | 1 | 2016 | 1004 | 0.080 |
Why?
|
Drug Monitoring | 3 | 2020 | 964 | 0.080 |
Why?
|
Patient Compliance | 1 | 2020 | 2693 | 0.080 |
Why?
|
Lung Diseases | 1 | 2019 | 1925 | 0.080 |
Why?
|
Procollagen | 2 | 2023 | 189 | 0.080 |
Why?
|
Patient Selection | 3 | 2017 | 4265 | 0.080 |
Why?
|
Diabetic Retinopathy | 1 | 2018 | 1299 | 0.080 |
Why?
|
Extracellular Space | 1 | 2011 | 565 | 0.080 |
Why?
|
Up-Regulation | 4 | 2021 | 4137 | 0.080 |
Why?
|
Breast Feeding | 1 | 2017 | 1364 | 0.080 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2021 | 2185 | 0.080 |
Why?
|
Morbidity | 3 | 2020 | 1758 | 0.080 |
Why?
|
Forecasting | 1 | 2018 | 2948 | 0.080 |
Why?
|
Acupuncture Therapy | 1 | 2013 | 486 | 0.080 |
Why?
|
Benzamides | 1 | 2014 | 1380 | 0.080 |
Why?
|
Brazil | 3 | 2018 | 1247 | 0.080 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 1141 | 0.080 |
Why?
|
Decision Support Techniques | 1 | 2019 | 2005 | 0.080 |
Why?
|
Epithelial Cells | 2 | 2021 | 3692 | 0.080 |
Why?
|
Immunity, Innate | 1 | 2020 | 3079 | 0.080 |
Why?
|
Patient Discharge | 4 | 2023 | 3474 | 0.070 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2012 | 775 | 0.070 |
Why?
|
Risk | 5 | 2018 | 9635 | 0.070 |
Why?
|
Triglycerides | 3 | 2021 | 2465 | 0.070 |
Why?
|
Metabolomics | 1 | 2017 | 1675 | 0.070 |
Why?
|
Irritable Bowel Syndrome | 1 | 2013 | 454 | 0.070 |
Why?
|
Glucagon-Like Peptide 1 | 2 | 2023 | 367 | 0.070 |
Why?
|
Population Surveillance | 1 | 2017 | 2598 | 0.070 |
Why?
|
Sodium | 2 | 2022 | 1594 | 0.070 |
Why?
|
Image Interpretation, Computer-Assisted | 2 | 2017 | 3411 | 0.070 |
Why?
|
Diabetes Mellitus, Type 1 | 2 | 2018 | 3440 | 0.070 |
Why?
|
Catheter Ablation | 1 | 2020 | 2776 | 0.070 |
Why?
|
Aspirin | 1 | 2018 | 3136 | 0.070 |
Why?
|
Odds Ratio | 4 | 2019 | 9681 | 0.060 |
Why?
|
Promoter Regions, Genetic | 1 | 2017 | 5800 | 0.060 |
Why?
|
Arrhythmias, Cardiac | 2 | 2013 | 2258 | 0.060 |
Why?
|
Body Weight | 1 | 2016 | 4630 | 0.060 |
Why?
|
Linear Models | 4 | 2017 | 5878 | 0.060 |
Why?
|
Medication Adherence | 1 | 2017 | 2189 | 0.060 |
Why?
|
Glucose | 3 | 2022 | 4354 | 0.060 |
Why?
|
Reproducibility of Results | 5 | 2023 | 20224 | 0.060 |
Why?
|
Japan | 2 | 2020 | 1418 | 0.060 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 3252 | 0.060 |
Why?
|
Blood Proteins | 2 | 2023 | 1186 | 0.060 |
Why?
|
Depression | 2 | 2021 | 8241 | 0.060 |
Why?
|
Health Services Accessibility | 1 | 2022 | 5511 | 0.060 |
Why?
|
Inflammatory Bowel Diseases | 2 | 2016 | 2442 | 0.060 |
Why?
|
Cost-Benefit Analysis | 3 | 2024 | 5538 | 0.060 |
Why?
|
Sodium-Glucose Transport Proteins | 1 | 2024 | 13 | 0.060 |
Why?
|
Administration, Intravaginal | 1 | 2024 | 149 | 0.060 |
Why?
|
Matrix Metalloproteinase 12 | 1 | 2024 | 44 | 0.060 |
Why?
|
Kidney Function Tests | 2 | 2017 | 681 | 0.060 |
Why?
|
Valsalva Maneuver | 1 | 2024 | 99 | 0.060 |
Why?
|
Anti-Retroviral Agents | 2 | 2024 | 1794 | 0.060 |
Why?
|
Piperazines | 1 | 2014 | 2552 | 0.060 |
Why?
|
Kansas | 1 | 2023 | 37 | 0.060 |
Why?
|
American Heart Association | 2 | 2021 | 1051 | 0.050 |
Why?
|
Europe, Eastern | 1 | 2023 | 72 | 0.050 |
Why?
|
Heterozygote | 2 | 2024 | 2792 | 0.050 |
Why?
|
Adrenomedullin | 1 | 2023 | 85 | 0.050 |
Why?
|
Hypovolemia | 1 | 2023 | 48 | 0.050 |
Why?
|
Postoperative Complications | 2 | 2017 | 15854 | 0.050 |
Why?
|
Physical Examination | 2 | 2019 | 1262 | 0.050 |
Why?
|
Aptamers, Nucleotide | 1 | 2024 | 162 | 0.050 |
Why?
|
Colon | 1 | 2011 | 1805 | 0.050 |
Why?
|
Mineralocorticoids | 1 | 2022 | 37 | 0.050 |
Why?
|
Renin-Angiotensin System | 2 | 2018 | 739 | 0.050 |
Why?
|
Fibrosis | 2 | 2023 | 2076 | 0.050 |
Why?
|
Organ Size | 2 | 2020 | 2268 | 0.050 |
Why?
|
Barbiturates | 1 | 2022 | 113 | 0.050 |
Why?
|
Carbamates | 1 | 2024 | 192 | 0.050 |
Why?
|
Immunohistochemistry | 1 | 2016 | 11117 | 0.050 |
Why?
|
Pyrimidines | 1 | 2014 | 3048 | 0.050 |
Why?
|
Cholesterol | 2 | 2021 | 2912 | 0.050 |
Why?
|
Ventricular Outflow Obstruction | 1 | 2024 | 262 | 0.050 |
Why?
|
Pain | 2 | 2015 | 5102 | 0.050 |
Why?
|
Activities of Daily Living | 2 | 2023 | 2433 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2021 | 16027 | 0.050 |
Why?
|
Electronics | 1 | 2023 | 317 | 0.050 |
Why?
|
Stress, Mechanical | 2 | 2017 | 1679 | 0.050 |
Why?
|
Child | 7 | 2024 | 80894 | 0.050 |
Why?
|
Psychomotor Agitation | 1 | 2023 | 307 | 0.050 |
Why?
|
Feasibility Studies | 2 | 2023 | 5311 | 0.050 |
Why?
|
Oligonucleotides | 1 | 2023 | 564 | 0.040 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 1 | 2021 | 150 | 0.040 |
Why?
|
Immunoglobulin G | 2 | 2023 | 4570 | 0.040 |
Why?
|
ROC Curve | 2 | 2019 | 3622 | 0.040 |
Why?
|
Glycine | 1 | 2024 | 672 | 0.040 |
Why?
|
Amyloidogenic Proteins | 1 | 2021 | 154 | 0.040 |
Why?
|
Alzheimer Disease | 1 | 2021 | 8747 | 0.040 |
Why?
|
Atrial Flutter | 1 | 2022 | 253 | 0.040 |
Why?
|
Enzyme Inhibitors | 2 | 2023 | 3722 | 0.040 |
Why?
|
Renin | 1 | 2022 | 648 | 0.040 |
Why?
|
Extracellular Matrix Proteins | 1 | 2024 | 835 | 0.040 |
Why?
|
Hypertonic Solutions | 1 | 2019 | 82 | 0.040 |
Why?
|
Erythropoiesis | 1 | 2023 | 693 | 0.040 |
Why?
|
Causality | 2 | 2016 | 1255 | 0.040 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2023 | 1133 | 0.040 |
Why?
|
Nebulizers and Vaporizers | 1 | 2019 | 139 | 0.040 |
Why?
|
Quebec | 1 | 2018 | 139 | 0.040 |
Why?
|
Americas | 1 | 2018 | 110 | 0.040 |
Why?
|
Treatment Failure | 2 | 2015 | 2664 | 0.040 |
Why?
|
Microcirculation | 1 | 2023 | 1282 | 0.040 |
Why?
|
Biological Availability | 1 | 2019 | 392 | 0.040 |
Why?
|
Tomography | 1 | 2020 | 442 | 0.040 |
Why?
|
Regression Analysis | 2 | 2018 | 6350 | 0.040 |
Why?
|
Lipoproteins, LDL | 1 | 2021 | 643 | 0.040 |
Why?
|
Immunoglobulin M | 1 | 2023 | 1528 | 0.040 |
Why?
|
Medication Therapy Management | 1 | 2019 | 131 | 0.040 |
Why?
|
Polyneuropathies | 1 | 2019 | 139 | 0.040 |
Why?
|
Angioedema | 1 | 2019 | 184 | 0.040 |
Why?
|
Tissue Plasminogen Activator | 1 | 2023 | 1163 | 0.040 |
Why?
|
Precipitating Factors | 1 | 2017 | 51 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 859 | 0.040 |
Why?
|
Hot Temperature | 2 | 2015 | 1440 | 0.040 |
Why?
|
Polysomnography | 2 | 2015 | 1865 | 0.040 |
Why?
|
South Africa | 1 | 2023 | 1871 | 0.040 |
Why?
|
Disease Management | 2 | 2021 | 2536 | 0.040 |
Why?
|
Demography | 1 | 2022 | 1642 | 0.040 |
Why?
|
Cerebral Infarction | 1 | 2022 | 975 | 0.040 |
Why?
|
Aldosterone | 1 | 2022 | 881 | 0.040 |
Why?
|
Residence Characteristics | 2 | 2019 | 2122 | 0.030 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2024 | 1360 | 0.030 |
Why?
|
Lipoproteins, HDL | 1 | 2021 | 682 | 0.030 |
Why?
|
Ontario | 1 | 2017 | 403 | 0.030 |
Why?
|
Administration, Inhalation | 1 | 2019 | 1169 | 0.030 |
Why?
|
Fluorescein Angiography | 1 | 2022 | 1086 | 0.030 |
Why?
|
Myocarditis | 1 | 2024 | 803 | 0.030 |
Why?
|
Preventive Health Services | 1 | 2021 | 568 | 0.030 |
Why?
|
Photography | 1 | 2019 | 537 | 0.030 |
Why?
|
Glycoproteins | 1 | 2024 | 2204 | 0.030 |
Why?
|
Administration, Oral | 1 | 2024 | 4043 | 0.030 |
Why?
|
Bronchodilator Agents | 1 | 2019 | 519 | 0.030 |
Why?
|
Nutrition Assessment | 1 | 2019 | 740 | 0.030 |
Why?
|
Apolipoproteins E | 1 | 2021 | 1459 | 0.030 |
Why?
|
Protein Precursors | 1 | 2020 | 1134 | 0.030 |
Why?
|
Netherlands | 1 | 2020 | 2274 | 0.030 |
Why?
|
Genetic Variation | 2 | 2023 | 6606 | 0.030 |
Why?
|
Pulmonary Ventilation | 1 | 2017 | 376 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2023 | 1736 | 0.030 |
Why?
|
Death | 1 | 2020 | 683 | 0.030 |
Why?
|
Retreatment | 1 | 2017 | 600 | 0.030 |
Why?
|
Nursing Homes | 1 | 2023 | 1084 | 0.030 |
Why?
|
Spirometry | 1 | 2018 | 928 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 2018 | 13696 | 0.030 |
Why?
|
Self Efficacy | 1 | 2019 | 643 | 0.030 |
Why?
|
Cardiotonic Agents | 1 | 2018 | 544 | 0.030 |
Why?
|
Death Certificates | 1 | 2015 | 175 | 0.030 |
Why?
|
South America | 1 | 2014 | 180 | 0.030 |
Why?
|
Periaqueductal Gray | 1 | 2015 | 111 | 0.030 |
Why?
|
Child, Preschool | 3 | 2024 | 42654 | 0.030 |
Why?
|
Leisure Activities | 1 | 2016 | 310 | 0.030 |
Why?
|
Diet Surveys | 1 | 2018 | 1161 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1795 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2019 | 2226 | 0.030 |
Why?
|
Pilot Projects | 2 | 2019 | 8730 | 0.030 |
Why?
|
Stochastic Processes | 1 | 2015 | 359 | 0.030 |
Why?
|
Capsaicin | 1 | 2015 | 235 | 0.030 |
Why?
|
Galectin 3 | 1 | 2016 | 240 | 0.030 |
Why?
|
Fibrinolytic Agents | 1 | 2023 | 2073 | 0.030 |
Why?
|
HIV-1 | 2 | 2024 | 6963 | 0.030 |
Why?
|
Drug Substitution | 1 | 2016 | 291 | 0.030 |
Why?
|
Technetium Tc 99m Sestamibi | 1 | 2014 | 184 | 0.030 |
Why?
|
Plasma | 1 | 2017 | 585 | 0.030 |
Why?
|
Pain Perception | 1 | 2015 | 198 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2021 | 14736 | 0.030 |
Why?
|
Carbon Dioxide | 1 | 2017 | 1149 | 0.030 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2017 | 1539 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 3 | 2021 | 18047 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2017 | 13576 | 0.030 |
Why?
|
Caspases | 1 | 2016 | 880 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2021 | 2353 | 0.030 |
Why?
|
Acupuncture Points | 1 | 2013 | 111 | 0.030 |
Why?
|
Galectins | 1 | 2016 | 296 | 0.030 |
Why?
|
Mendelian Randomization Analysis | 1 | 2018 | 1037 | 0.030 |
Why?
|
Inflammation | 2 | 2024 | 10863 | 0.030 |
Why?
|
Radiology, Interventional | 1 | 2017 | 483 | 0.030 |
Why?
|
Phenotype | 2 | 2024 | 16716 | 0.030 |
Why?
|
Waist Circumference | 1 | 2016 | 935 | 0.030 |
Why?
|
Independent Living | 1 | 2016 | 580 | 0.030 |
Why?
|
Cardiovascular System | 1 | 2020 | 838 | 0.030 |
Why?
|
Australia | 1 | 2016 | 1265 | 0.020 |
Why?
|
Drug Resistance | 1 | 2018 | 1595 | 0.020 |
Why?
|
Propensity Score | 1 | 2019 | 1955 | 0.020 |
Why?
|
Staining and Labeling | 1 | 2016 | 1081 | 0.020 |
Why?
|
Lidocaine | 1 | 2015 | 545 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2018 | 2596 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2022 | 2783 | 0.020 |
Why?
|
Patient Care Team | 1 | 2023 | 2529 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2018 | 2363 | 0.020 |
Why?
|
Logistic Models | 2 | 2016 | 13323 | 0.020 |
Why?
|
Inpatients | 1 | 2023 | 2569 | 0.020 |
Why?
|
Angina, Unstable | 1 | 2015 | 893 | 0.020 |
Why?
|
Action Potentials | 1 | 2019 | 1838 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 3811 | 0.020 |
Why?
|
Age of Onset | 1 | 2018 | 3345 | 0.020 |
Why?
|
Neutrophils | 1 | 2023 | 3785 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2024 | 4940 | 0.020 |
Why?
|
Medical Oncology | 1 | 2022 | 2348 | 0.020 |
Why?
|
Asymptomatic Diseases | 1 | 2013 | 590 | 0.020 |
Why?
|
Tandem Mass Spectrometry | 1 | 2017 | 1197 | 0.020 |
Why?
|
Pregnancy | 2 | 2023 | 30198 | 0.020 |
Why?
|
Reference Values | 1 | 2017 | 4941 | 0.020 |
Why?
|
Pregnancy Outcome | 1 | 2021 | 2961 | 0.020 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2013 | 371 | 0.020 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2018 | 997 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2661 | 0.020 |
Why?
|
Benzazepines | 1 | 2012 | 311 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2017 | 2727 | 0.020 |
Why?
|
Sex Distribution | 1 | 2015 | 2281 | 0.020 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2018 | 1903 | 0.020 |
Why?
|
Pain Threshold | 1 | 2013 | 606 | 0.020 |
Why?
|
Acetaminophen | 1 | 2013 | 556 | 0.020 |
Why?
|
Tomography, Optical Coherence | 1 | 2022 | 2957 | 0.020 |
Why?
|
Viral Load | 1 | 2018 | 3398 | 0.020 |
Why?
|
Biopsy | 1 | 2020 | 6808 | 0.020 |
Why?
|
Cholesterol, HDL | 1 | 2015 | 1820 | 0.020 |
Why?
|
Health Personnel | 1 | 2022 | 3381 | 0.020 |
Why?
|
Polymorphism, Genetic | 1 | 2019 | 4250 | 0.020 |
Why?
|
Anti-HIV Agents | 1 | 2024 | 4571 | 0.020 |
Why?
|
Cues | 1 | 2013 | 884 | 0.020 |
Why?
|
Insurance Coverage | 1 | 2019 | 1946 | 0.020 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 2277 | 0.020 |
Why?
|
Stress, Physiological | 1 | 2015 | 1410 | 0.020 |
Why?
|
Health Behavior | 1 | 2019 | 2647 | 0.020 |
Why?
|
Iron | 1 | 2016 | 1815 | 0.020 |
Why?
|
Anesthetics, Local | 1 | 2015 | 1003 | 0.020 |
Why?
|
Carotid Artery Diseases | 1 | 2014 | 878 | 0.020 |
Why?
|
Reward | 1 | 2015 | 984 | 0.020 |
Why?
|
Genetic Testing | 1 | 2021 | 3587 | 0.020 |
Why?
|
Tachycardia, Ventricular | 1 | 2017 | 1309 | 0.020 |
Why?
|
Hospitals | 1 | 2021 | 3905 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2015 | 4859 | 0.020 |
Why?
|
Insurance, Health | 1 | 2019 | 2518 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2019 | 4427 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2013 | 2106 | 0.020 |
Why?
|
Public Health | 1 | 2020 | 2681 | 0.020 |
Why?
|
Cell Count | 1 | 2011 | 1833 | 0.020 |
Why?
|
Lipids | 1 | 2018 | 3344 | 0.020 |
Why?
|
Receptors, Cell Surface | 1 | 2016 | 2819 | 0.020 |
Why?
|
Epithelium | 1 | 2011 | 1609 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2019 | 3800 | 0.020 |
Why?
|
Length of Stay | 1 | 2019 | 6516 | 0.020 |
Why?
|
Cholesterol, LDL | 1 | 2015 | 2398 | 0.020 |
Why?
|
Recovery of Function | 1 | 2016 | 2990 | 0.020 |
Why?
|
Medicare | 1 | 2024 | 6881 | 0.020 |
Why?
|
Motor Activity | 1 | 2015 | 2720 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2011 | 2862 | 0.020 |
Why?
|
Massachusetts | 1 | 2018 | 8902 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2013 | 6238 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2017 | 4209 | 0.010 |
Why?
|
Liver | 1 | 2020 | 7570 | 0.010 |
Why?
|
Overweight | 1 | 2015 | 2445 | 0.010 |
Why?
|
Pain Measurement | 1 | 2013 | 3579 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2024 | 36849 | 0.010 |
Why?
|
Anticoagulants | 1 | 2016 | 4842 | 0.010 |
Why?
|
Genotype | 1 | 2015 | 13038 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 7453 | 0.010 |
Why?
|
Cerebral Cortex | 1 | 2015 | 5830 | 0.010 |
Why?
|
Infant | 1 | 2020 | 36512 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2017 | 7955 | 0.010 |
Why?
|
Mutation | 1 | 2019 | 30230 | 0.010 |
Why?
|